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TITLE: Hepcare Europe - Bridging the gap in the treatment of Hepatitis C: Study Protocol 
 
ABSTRACT:  
Background. Hepatitis C (HCV) infection is highly prevalent among people who inject drugs 
(PWID). Many PWID are unaware of their infection and few have received HCV treatment. 
Recent developments in treatment offer cure rates >90%. However, the potential of these 
treatments will only be realised if HCV identification among PWID with linkage to treatment 
is optimised. This paper describes the Hepcare Europe project, a collaboration between five 
institutions across four member states (Ireland, UK, Spain, Romania), to develop, implement 
and evaluate interventions to improve the identification, evaluation and treatment of HCV 
among PWID.   
Research design and methods. A service innovation project and a mixed-methods, pre-post 
intervention study, Hepcare will design and deliver interventions in Dublin, London, Seville 
and Bucharest to enhance PWID engagement and retention in the cascade of HCV care. The 
feasibility, acceptability, potential efficacy and cost-effectiveness of these interventions to 
improve care processes and outcomes among PWID will be evaluated.  
Conclusions. Hepcare has the potential to make an important impact on patient care for 
marginalised populations who might otherwise go undiagnosed and untreated. Lessons 
learned from the study can be incorporated into national and European guidelines and 
strategies for HCV.  
 
KEYWORDS: Hepatitis C, HCV, PWID, homeless, prisoners, screening, linkage to care, 
treatment, interventions, Europe 
 
1. BACKGROUND 
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In the European Union (EU) and European Economic Area (EEA), approximately 5.6 million 
people have been infected with the Hepatitis C Virus (HCV) (1.1% of the general 
population). However, national estimates of seroprevalence vary widely, from 0.1% in 
Belgium, Ireland and the Netherlands to 5.9% in Italy (1). Approximately 50-80% of 
individuals infected with HCV will develop chronic infection which is associated with liver 
cirrhosis and hepatocellular carcinoma (HCC) (2, 3). 
 
People who inject drugs (PWID) and ex-PWID bear the greatest burden of HCV infection in 
Europe and account for the majority of new infections. Estimates suggest that of 1.2 million 
current PWID in the EU/EFTA area, 0.7 million have been infected with HCV and 0.5 
million are chronically infected (4). Prevalence varies substantially between countries: 
according to the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), 
HCV antibody (anti-HCV) prevalence among national samples of PWID in 2014–15 ranged 
from 16%-84% (5). Modelling studies predict substantial increases in liver disease among 
ageing HCV-infected PWID populations (6, 7).  
 
Despite the high prevalence of HCV among PWID, many are unaware of their infection and 
few have received treatment. Estimates of undiagnosed infection among PWID in Europe 
range from 24%-76% (8). Among PWID diagnosed with chronic hepatitis C (CHC), the 
proportion entering HCV treatment is low (range 1–19%) (8). Low treatment rates are in part 
explained by the suboptimal referral of PWID post-diagnosis to specialist secondary care for 
evaluation and treatment of HCV (9), and also by poor attendance and defection from 
secondary care among those who are referred (10).  
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The World Health Organization’s (WHO) recently developed Global Health Sector Strategy 
(GHSS) on viral hepatitis aims to eliminate viral hepatitis as a major public health threat, 
including the following targets for 2030 (11): 
 Reduce CHC incidence by 90%;  
 Reduce HCV-related mortality by 65%; 
 Diagnose 90% of CHC infections;  
 Treat 80% of eligible persons with CHC. 
To achieve these targets, it is essential that countries increase prevention, testing and linkage 
of diagnosed individuals to treatment. As many PWID remain unaware of their infection 
and/or are not accessing HCV care, it is evident that new strategies to reach such individuals 
are necessary, including new testing strategies to increase the number diagnosed, and 
improved care pathways to ensure those diagnosed are successfully linked to HCV evaluation 
and treatment.  
 
Previous research has identified a range of barriers to PWID accessing HCV screening, 
evaluation and treatment, including: anticipated stigma and discrimination, restrictions 
around HCV treatment eligibility, inconvenience of travelling to testing sites and hospitals, 
fear of HCV investigations and treatment side-effects, perceptions of HCV as relatively 
benign, being asymptomatic, and competing priorities (12, 13). Further barriers are a low 
level of awareness and HCV literacy among patients, healthcare providers, policy-makers, 
and the general public and limited attention, resources and commitment to HCV care at the 
political level (14). 
 
Recent developments in HCV diagnostics and treatment can enhance access to, and uptake 
of, HCV care among PWID. Recently licensed point of care tests (POCTs) for HCV, 
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including rapid diagnostic tests (RDTs) from finger prick blood samples and oral secretions, 
are portable, easy to use and often less invasive than traditional venous blood sampling. Thus, 
they have the potential to make HCV diagnosis more available for many populations by 
facilitating outreach of screening beyond clinical settings and personnel. As most POCTs 
provide a result within 5-30 minutes (15), they may also enhance retention of patients in the 
subsequent cascade of HCV care.  
 
Likewise, the replacement of liver biopsy by transient elastography (FibroScanTM, Echosens, 
Paris), for the staging of liver fibrosis, enhances opportunities for the extension of specialist 
evaluation of HCV disease from hospital into community settings to reach more patients. In 
addition to being non-invasive, the FibroScan has advantages, including: (i) being portable, it 
can be transported to community sites to assess patients; (ii) individuals can relatively easily 
be trained in its use; and (iii) scans can be conducted within less than five minutes and results 
given immediately to patients, which may enhance their engagement with HCV treatment as 
previous studies have shown how clinical markers can impact patients’ perceptions of HCV 
disease (12, 16).  
 
However, the revolution in HCV treatment is the most significant advance in HCV care. The 
replacement of pegylated interferon and ribavirin with new interferon-free direct acting 
antiviral agents (DAAs) has reduced HCV treatment times to 8-12 weeks, improved safety 
profiles, and increased cure rates to >90% of cases (17, 18). These relatively simple, tolerable 
and highly effective treatments are improving treatment uptake among patients and 
enhancing opportunities for provision of treatment in community settings (19).  
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These developments in treatment make HCV elimination among PWID feasible (14). 
Modelling studies have shown that if treatment is delivered at the right scale, it can have a 
major preventative impact on HCV transmission (20). A challenge is the current high cost of 
the DAA treatments, which is a barrier even for high-income countries to deliver treatment at 
the scale needed. If price reform is not achieved, this could undermine countries efforts to 
impact upon the growing liver disease burden (21). However, even if DAA treatments were 
affordable and accessible to all, the full clinical impact of these therapies will be contingent 
on engaging and retaining PWID in the HCV cascade of care (22).  
 
Attention now needs to turn to developing evidence-based, culturally appropriate strategies to 
improve diagnosis and linkage to care of PWID (14, 22). Several authors have argued that to 
optimise the potential of the new HCV therapies when they become more widely available, 
now is the time to scale up prevention, educate patients and healthcare providers, and identify 
the best interventions to enhance delivery of screening, assessment and treatment (14, 23). 
 
A recent systematic review and meta-analysis of operational interventions to improve 
engagement and retention along the HCV cascade of care identified some effective strategies 
(22), including: reminders to clinicians regarding testing, HCV education and pre-test 
counselling accompanied by on-site testing, facilitated referral to specialist care, integration 
of mental health and substance misuse management with HCV treatment services, and nurse-
led educational sessions about HCV treatment. This review did not restrict studies to PWID, 
although most studies were conducted amongst this population. A more recent systematic 
review which focused on PWID, people who use drugs and OST populations arrived at 
similar conclusions, including the effectiveness of dried blood spot (DBS) testing to enhance 
testing uptake (24). HCV treatment in almost all studies within both reviews was interferon-
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based. Both reviews concluded that many of the studies were of low quality and further 
operational research is needed to optimise hepatitis care services (22, 24). The design and 
evaluation of interventions which simplify the HCV cascade of care in the new DAA 
treatment era, and which target multiple components within the care cascade, was identified 
as a research priority (24).  
 
It is likely that multidisciplinary, integrated models of HCV care involving partnership 
between HCV specialists and community healthcare providers (14), and the continuing 
extension of HCV care into community settings, will be the appropriate foundation for HCV 
services adapted to the needs of PWID. The traditional location of HCV assessment and 
treatment in hospitals is a model of care ill-adapted to the needs and life circumstances of 
many PWID (14). At the same time, the limited infrastructure and HCV knowledge in OST 
clinics and primary care centres restrict their ability to provide HCV assessment and 
treatment unsupported (14). Thus, for the foreseeable future, a multidisciplinary, partnership 
approach is likely to be important. Various integrated care models have been demonstrated to 
successfully enhance HCV assessment and interferon-based treatment of PWID, including 
telemedicine clinics between specialists and primary care providers (25), and on-site HCV 
nursing and specialist support within OST clinics and community health centres (23, 26). 
 
The epidemiological, demographic and socio-political situation with regard to HCV varies 
across Europe and there is diversity in countries programmatic responses to the epidemic 
(21). Comprehension of such issues and collaboration between key organisations and member 
states will be important for any chance of eliminating HCV (21). The relatively free 
movement of people between member states means that interventions will have greater 
effectiveness if countries work together and coordinate their activities. Collaboration and the 
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pooling of intellectual, research and political resources will hasten learnings regarding 
optimum HCV service provision. 
 
Hepcare Europe is an EU-supported project involving collaboration between five institutions 
across four member states, including: University College Dublin (UCD), Ireland; Servicio 
Andaluz De Salud (SAS), Spain; Spitalul Clinic de Boli Infectioase si Tropicale “Dr. Victor 
Babes” (SVB), Romania; and University of Bristol (UoB) and University College London 
(UCL) in the United Kingdom. The project aims to develop, implement and evaluate 
interventions to improve HCV diagnosis, evaluation and treatment among PWID and linked 
groups such as prisoners and the homeless, across a range of settings in Dublin, Seville, 
Bucharest and London. We will develop outreach and integrated models of HCV care in the 
participating sites that are tailored to their health service infrastructure and population needs, 
to improve PWID engagement and retention along the cascade of HCV care. Interventions 
will include point-of-care diagnostics, nurse outreach, community-based evaluation of HCV 
disease, patient and healthcare professional education, and peer support. We will evaluate the 
feasibility, acceptability, potential efficacy and cost-effectiveness of the interventions within 
the different settings in order to provide a better understanding of how improvements to the 
care of PWID can be achieved.  
 
1.1 Specific Objectives include:  
Primary objectives 
 To determine the feasibility, acceptability and potential efficacy of the various 
components of the Hepcare Europe package of interventions across the different 
settings to enhance HCV identification, evaluation and treatment among PWID and 
linked groups. Feasibility will be determined by examining the uptake of the 
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interventions across the different settings. Acceptability will be determined by 
examining participants’ experiences of and satisfaction with the interventions. 
Potential efficacy will be assessed by examining the number and proportion of 
participants diagnosed, evaluated, treated, and attained SVR, pre- and post-
intervention. 
Secondary objectives 
 To determine how the cost-effectiveness of the interventions might vary across 
different EU settings, and use the results to help guide decision criteria for when 
specific case-finding and care strategies should be used; 
 To engage with key stakeholders, nationally and in Europe, to ensure our findings 
contribute to HCV policy and practice. 
 
2. CONTEXT AND METHOD 
2.1 Study Design and Settings  
Hepcare Europe is a service innovation project and a prospective, observational, mixed-
methods, pre-post intervention study.  
 
Fieldwork in relation to the Hepcare interventions will take place in four sites (Dublin, 
London, Seville and Bucharest) and a health economics analysis will be conducted in the fifth 
site (Bristol). Taken together, participating sites have different histories and policies in 
relation to opioid substitution treatment (OST), harm reduction and access to the new HCV 
therapies and have different models of primary care (Table 1).  
 
Dublin, Ireland 
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Estimates suggest 20,000-30,000 people in Ireland are chronically infected with HCV  (27). 
Injecting drug use is the main risk factor in 80% of HCV cases (28). Studies indicate a 
prevalence of HCV antibodies (anti-HCV) among PWID of 62-81% (29-32). According to a 
recent study, between the years 1991-2014, an estimated 12,423 of approximately 16,400 
PWIDs have been infected with HCV, with 9,317 chronically infected (27).  
 
Methadone is the only form of OST prescribed in Ireland and is provided by addiction 
treatment centres, specialised GPs and in prisons (33). Ireland has three models of needle and 
syringe programmes (NSP), including: fixed site facilities, outreach syringe provision and 
pharmacy-based programmes (34). 
 
National HCV screening guidelines have recently been published (35) identifying risk groups 
for screening, including PWID and linked groups such as prisoners and homeless people. The 
guidelines highlight that novel strategies and/or extra support may be required to engage 
prisoners and homeless people with screening and to enable their linkage to specialist HCV 
care and treatment. A National Hepatitis C Treatment Programme oversees access to DAA 
treatments on a phased basis. Until 2017, access was organised according to clinical need and 
restricted to those who were infected with HCV through blood and blood-products and those 
scoring >8.5 kPa on FibroScan. In early 2017 the criteria were revised to remove this 
threshold, but a limited healthcare budget and the high cost of DAAs continue to restrict the 
numbers who can avail of treatment. 
 
The Hepcare Study in Dublin is taking place in two settings: (i) a closed, medium-security 
prison for adult males located in the centre of Dublin, which has the largest prison population 
in Ireland; and (ii) OST-prescribing GP practices in North Dublin. Both settings are within 
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the catchment area of the participating centre in Ireland, i.e. the Mater Misericordiae 
University Hospital, an academic teaching hospital in Dublin’s North Inner City. The 
hospital’s Infectious Diseases Department cares for a large number of patients with HIV 
and/or HCV. 
 
London, UK 
Estimates suggest approximately 214,000 people are living with CHC in the UK (36). 
Injecting drug use is the risk factor in 90% of HCV cases (37). Around half of PWID are 
thought to be anti-HCV positive in England (52%) and Wales (53%), with levels being lower 
in Northern Ireland (23%) and higher in Scotland (58%) (36).  
 
In the UK, options for OST include methadone, buprenorphine, and rarely diamorphine. OST 
is delivered through specialist outpatient drug treatment services and shared care 
arrangements with GPs. NSP are provided mainly through pharmacies and drug treatment 
services, but also via street outreach workers and mobile van units (37). According to Public 
Health England’s “Shooting Up” report, trends in injecting drug use in the UK are changing, 
with a growing number of people injecting amphetamines and amphetamine-type drugs such 
as mephedrone (38). There has been a recent sharp increase in HIV and HCV infections in 
South-West Wales linked to a move from opiate injecting toward injecting newly emerged 
drugs such as mephedrone (39). A HIV outbreak among PWID in Glasgow was also reported 
in 2015 (38).  
 
In England, access to DAA treatments is organised by 22 Operational Delivery Networks 
who provide clinical leadership over a given geography and are responsible for delivering 
HCV treatment under certain conditions. NHS guidance in 2015 was that those with 
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Genotype 1 and cirrhosis, and those with decompensated cirrhosis (any genotype) were 
eligible for treatment with the new oral drugs (40). Eligibility criteria have since been relaxed 
and currently all genotypes regarding of stage of fibrosis are eligible for DAAs (41).  
 
The Hepcare Study in London is taking place in two settings: (i) using the resources and 
Mobile Health Unit of the “Find&Treat” homeless health team of University College London 
NHS Trust, Hepcare will conduct outreach to selected sites within underserved communities 
in metropolitan London. Sites to be visited by the mobile van and/or screening staff will 
include homeless residential hostels, day centres and drug services; and (ii) OST-prescribing 
GP practices. 
 
Bucharest, Romania 
Approximately 489,000 people are estimated to have CHC in Romania (42). The majority of 
cases were infected nosocomially before 1990 (42). However, in the last decade there has 
been an increasing trend of HCV infections among PWID, with seroprevalence rates among 
PWID mounting from 47.6% in 2004 to 82.4% in 2012 (43).  
 
HIV and Hepatitis B (HBV) infection among PWID also represent a challenge for the 
healthcare system. Rates of HIV and HBV were low among PWID until 2011, when an 
explosive increase in blood borne virus infections in drug users was reported, with HIV 
prevalence among PWID rising from 4.1% in 2010 to 49.2% in 2013, and HBV prevalence 
from 13.1% to 27.7% in the same period (44). This increase was driven by the replacement of 
heroin with new psychoactive substances called “ethnobotanicals”, which have amphetamine-
like effects, cause a high addiction and need for multiple administrations per day. This 
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change in injecting trends coincided with reduced funding of NSP and consequent shortage of 
clean needles (43, 45).  
 
In Romania, OST (methadone, buprenorphine, or combination buprenorphine/naloxone) is 
delivered mainly through public medical units and Drug Prevention, Evaluation and 
Counselling Centres in Bucharest, as well as in prisons. One NGO and three private providers 
also provide OST. Coverage is considered low however, with an estimated 1 (<1-1) OST 
recipient per 100 PWID (46). NSP are provided by NGOs in Bucharest and two adjacent 
counties through outreach programmes in fixed locations and via street workers and a mobile 
team. Most injecting drug use is centred in Bucharest, where according to the latest reported 
data from 2013, there were an estimated 6288 PWID (43). 
 
In 2014, supported by Norwegian Funds, a national project was initiated to create a national 
hepatitis registry. Secondary objectives of the project include testing for HIV and hepatitis in 
vulnerable groups, improving access to medical services and NSP for PWID, providing HCV 
education and training for healthcare professionals, and increasing public awareness of HCV, 
HBV and HIV.  
 
Access to interferon (IFN)-free therapies is restricted in Romania. In 2015-2016, 5000 
patients with compensated cirrhosis were treated with IFN-free regimens, while non-cirrhotic 
patients were eligible for IFN-based therapies only. Access was expanded in 2017 to 
decompensated cirrhotic patients, non-cirrhotic F3 patients, non-cirrhotic F2 patients with a 
contraindication to IFN-treatment, F2 patients with cryoglobulinemia, liver transplant 
recipients with recurrence of HCV, dialysis patients (F2-F4) and medical staff (47). In 
addition to restrictions relating to stage of fibrosis, patients with HIV/HCV co-infection are 
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required to give a negative drug test to receive reimbursed DAA therapy. However, those 
mono-infected with HCV do not seem to have the same requirement (41). 
 
The Hepcare Study in Bucharest is taking place in a range of settings, including: (i) night 
shelters and NGOs caring for homeless people; (ii) OST centres; (iii) an inpatient drug 
treatment unit; and (iv) prisons. Patients from these sites will be referred to the participating 
center in Romania, i.e. the Victor Babes Clinical Hospital for Infectious and Tropical 
Diseases. The hospital serves a catchment of 50% of the Bucharest region and six additional 
surrounding districts and has been a centre for HIV / AIDS since 1989 (a University hospital 
since 1976).  
 
Seville, Spain 
Approximately 472,000 adults are estimated to have CHC in Spain (48). Over 300,000 
individuals in Spain have a lifetime history of injecting drugs and estimates of HCV 
prevalence among PWID are 60-80% (49).  
 
In Spain, OST (methadone or buprenorphine/naloxone combination) is delivered mainly 
through specialised outpatient drug treatment centres, some primary care centres, inpatient 
facilities and prisons. Harm reduction services are provided through social emergency 
centres, mobile units, pharmacies and prisons. Most harm reduction programmes include 
preventive educational interventions, NSP, BBV testing, and HAV / HBV vaccinations (50). 
Spain also has 13 facilities for supervised drug consumption (50). 
 
In 2015, a National Strategic Plan for tackling HCV was published (51), consisting of four 
strategic directions: 
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 Establish the prevalence and epidemiology of HCV infection in Spain, promote early 
diagnosis in priority populations, primary prevention of HCV infection and secondary 
prevention of HCV-related complications; 
 Define the scientific-clinical criteria for establishing the appropriate therapeutic 
strategy for CHC patients, including prioritizing those with most clinical need for 
initial access to DAAs;  
 Establish coordination mechanisms to guarantee the implementation of the Strategy; 
 Foster knowledge regarding HCV prevention, diagnosis and treatment in the National 
Health System. 
 
The first strategic line of the Spanish Plan regarding early diagnosis has not been developed 
because all funding has been diverted towards the second strategic line referring to HCV 
treatment as a large burden of previously diagnosed infections are still pending treatment in 
Spain. Priority groups identified by the Strategy for DAA treatments include: patients with 
advanced liver fibrosis (F2-F4) or extra-hepatic manifestations of HCV, patients on transplant 
waiting lists, liver transplant recipients with recurrence of HCV, non-liver transplant HCV 
patients, and patients who have not responded to triple therapy with first generation protease 
inhibitors. In June 2017, access to DAA treatment was no longer restricted to priority groups. 
Currently, any HCV-infected patient can be treated with DAA combinations, regardless of 
fibrosis or any other clinical situation (41).  
 
The Hepcare Study in Seville is taking place in a number of settings in the province of 
Seville, corresponding to the area of the participating center in Spain (i.e. the Hospital 
Universitario de Valme), including: (i) NGOs and other organisations dedicated to homeless 
people; (ii) drug addiction units; (iii) therapeutic communities; and (iv) OST prescribing 
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primary care centres. The Hospital is a tertiary care university hospital and its Infectious 
Diseases Unit is the premiere unit in the region.  
 
2.2 Study populations, sampling and recruitment 
The project is focused on three target groups:  
(i) PWID at-risk of or diagnosed with HCV, and linked groups such as people who 
are homeless, sex-workers, and prisoners;  
(ii) Healthcare providers working with the aforementioned groups, including: GPs, 
Practice Nurses, Counsellors, Social Workers and Outreach workers; and  
(iii) Organisations involved in influencing health systems, including: national patient 
support groups, national bodies in participating countries, and key European and 
international bodies. 
 
Population, convenience or purposive sampling will be conducted depending on the aims of 
the work package and setting. 
 
2.3 Hepcare Work Packages  
Hepcare Europe includes the following inter-connected work packages (WPs) (see Figure 1 
and Table 2): 
 
2.3.1  HepCheck 
This WP will develop, implement and evaluate interventions to enhance HCV screening of 
PWID and linked groups, who although at risk for and often infected with HCV, are 
frequently marginalized in their engagement with health services. HepCheck will outreach 
screening to these groups through their points of contact with services in the community (e.g. 
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OST clinics, homeless services, prisons) and use a point-of-care testing strategy. A meta-
analysis comparing HCV POCTs with reference tests found that on pooled analysis POCTs 
were highly accurate for diagnosing HCV, although authors cautioned care in the choice of 
test as the sensitivity and specificity of individual tests varied widely (52). HepCheck will use 
the OraSure Technologies OraQuick HCV rapid antibody test which samples oral/salivary 
fluid and avoids the need for phlebotomy. According to a field study, the sensitivity of the 
test was 97.8% and specificity 100% (53).  
 
Individuals attending participating services in the four sites (Dublin, London, Bucharest, 
Seville) will be offered HCV screening using the OraQuick test. Those who accept the 
screening offer and test antibody positive (Ab+), and individuals who indicate they have 
already been diagnosed with HCV but have not received or engaged with specialist follow-
up, will be offered further evaluation for HCV, including: HCV polymerase chain reaction 
(PCR) and antigen test to determine whether they have chronic infection, FibroScan to assess 
the extent of liver disease, and referral for HCV treatment if eligible. Individuals once 
referred to specialist hepatology/infectious diseases services will be assessed as to their 
suitability for HCV treatment and any barriers to treatment will be identified. The original 
service from which participants were recruited, with the involvement of allied health 
professionals, can develop a care plan to address the issues preventing treatment. HepCheck 
will thus address engagement with HCV evaluation and treatment as well as screening, by 
using the POCT offer as the entry point into the cascade of care required to be cured of HCV.  
 
A minimum of 2,000 individuals will be screened for HCV across the four sites. We will 
evaluate the feasibility, acceptability and potential efficacy of the screening interventions for 
individuals attending homeless and other services in the partner sites, including establishing 
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the utility of POCT with HCV oral tests in diverse populations and different 
countries/settings. A quantitative audit of access to HCV treatment and of treatment 
outcomes in HCV-infected individuals identified during the screening process will be 
conducted. Qualitative interviews with a purposive sample of participants will examine 
acceptability of the interventions and barriers and facilitators to HCV treatment completion.  
 
2.3.2  HepLink 
This WP will develop, implement and evaluate a complex intervention to improve linkage to 
HCV evaluation and treatment among OST patients attending general practice and 
specialised OST centers. In many EU countries, including Ireland, Spain and the UK, general 
practice is increasingly involved in providing OST and continuing care for PWID. It is thus a 
key setting to target to address HCV-related morbidity and mortality among PWID. In 
Romania, OST is not prescribed by GPs but is provided through specialised centers. GPs and 
other OST prescribers often have long-standing relationships with their OST patients and as 
such can facilitate access to HCV evaluation and treatment among PWID where shared care 
partnerships with secondary/tertiary providers are developed. 
 
HepLink will outreach a HCV-trained liaison nurse into GP practices and OST centers to 
optimise interaction and integration between primary and secondary care. S/he will conduct 
on-site specialist evaluation of HCV disease (including FibroScan) in the general practice / 
OST center setting, and assist in referring HCV-infected patients to a hepatology/Infectious 
Diseases service for HCV treatment. S/he will educate OST providers, GPs, practice staff and 
patients on HCV and developments in its diagnosis and treatment and ensure that patients’ 
HCV testing and other blood borne virus screening and vaccinations are up-to-date. Research 
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has shown that practitioner education and nurse liaison can increase rates of HCV screening 
and linkage to specialist care in general practice (54). 
 
A central component of the intervention will be the staging of liver fibrosis among HCV-
infected patients using a FibroScan. Studies have shown the FibroScan to be equivalent to 
liver biopsy, although obesity, female sex, operator experience, and age older than 52 may 
give invalid results (55, 56). Currently, in many HCV treatment guidelines, a FibroScan is 
used to determine eligibility for state-supported HCV treatment utilizing DAA therapies. 
Thus the FibroScan has become an essential component of the evaluation of patients with 
HCV.  
 
Twenty-four OST-prescribing GP practices and OST centers and 240 patients will be 
recruited across the four participating sites. In addition to developing and delivering the 
complex intervention, we will evaluate the intervention’s feasibility, acceptability and likely 
efficacy within the different countries / health systems. An audit of patients’ clinical records 
will be conducted at baseline and 6-months post-intervention to examine HCV care processes 
and outcomes following the intervention. Qualitative interviews with a purposive sample of 
OST providers and patients will assess the intervention’s acceptability.  
 
2.3.3  HepFriend  
This WP will develop and implement peer support interventions to enhance engagement with 
HCV screening, assessment and treatment within the HepCheck and HepLink WPs. Peers are 
individuals with similar life or disease experiences to the clients they are supporting, i.e. 
HCV infection / drug misuse / homelessness. We will recruit, train and support peers to 
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improve HCV care integration between community and specialist services following the 
development of the HepCheck and HepLink interventions.  
 
Peers will be trained to assist the clinical teams in HepCheck and HepLink with POCT, 
FibroScanning, and conducting pre-treatment assessments. They will receive training in how 
to support people through the HCV cascade of care, including those who are eligible for or 
undergoing HCV treatment. Peers will support clients by giving advice and education around 
the care pathway, accompanying clients to clinical appointments if desired, reminding clients 
of appointments, and meeting clients for social support. HepFriend will be conducted at all 
four sites. 
 
We will determine the feasibility, acceptability and potential efficacy of the peer support 
interventions combined with HepCheck and HepLink, to improve HCV case detection and 
treatment uptake and outcomes in the diverse populations and different countries/settings. 
The client and peer experience of peer support will be assessed by qualitative interviews. 
 
2.3.4  HepEd  
There have been a number of developments in HCV diagnostics and treatment in recent 
years. However, a cultural lag has been identified between such developments and societal 
understandings of them (57). This WP will develop and deliver educational interventions to 
prepare affected communities for HCV testing, assessment and treatment and to prepare 
healthcare providers to act as partners in a shared care primary/secondary partnership for 
treatment of HCV. These interventions will be utilised within the other WPs of the project, 
i.e. HepCheck, HepLink and HepFriend.  
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HepEd will: 
 Develop and implement a programme of multidisciplinary, inter-professional 
education on HCV for healthcare providers. This will include the hosting of 
Masterclasses on HCV and advances in its diagnosis and treatment for a 
minimum of 30 healthcare providers at each of the four sites (i.e. 120 
providers in total) and the development of video and online resources to reach 
a wider audience. 
 Develop and/or adapt educational materials for use in affected communities, 
including PWIDs. This will include educational materials to prevent those 
who test negative from subsequently acquiring HCV.  
 Develop and adapt training materials for peers (i.e. HepFriend).  
 
To evaluate the impact of the HCV masterclasses, attendees will be asked to complete pre- 
and post-intervention questionnaires on their experience of the masterclass and the extent to 
which they found it of value in providing HCV care for patients.  
 
2.3.5  HepCost  
This WP will evaluate the cost-effectiveness of the various Hepcare interventions in the 
different countries / settings and use the results to help guide decision criteria for when 
specific case-finding and care strategies should be used. The four interventions to be 
evaluated are HepCheck, HepLink, HepFriend and HepEd.  
 
An existing dynamic compartmental model of HCV disease progression, screening, treatment 
and transmission among PWID and non or ex-PWID will be adapted to evaluate the Hepcare 
interventions. The model will initially be parameterised to evaluate each intervention in a 
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specific setting, and then adapted to consider the other settings. One setting will be modelled 
as a base case for each intervention and then the other settings will be modelled as a 
sensitivity analysis based on that primary setting. We will perform extensive sensitivity 
analysis to explore thresholds of cost-effectiveness in terms of minimum levels of 
intervention effect or testing yield, as well as what key factors and changes to the intervention 
may increase or decrease cost-effectiveness.  
 
2.3.6  Dissemination  
This WP aims to maximise the dissemination of findings from the project and its impact on 
HCV policy and practice nationally and in Europe. In addition to disseminating findings to 
healthcare professionals, affected communities, and the scientific community through 
conferences, peer-reviewed publications and social media, we will proactively engage with 
key stakeholders and policy-makers, nationally and in the EU, including service-user 
organizations, NGOs, key people responsible for national HCV policy at each site, and EU 
HCV and drug policy agencies. 
 
2.3.7  Evaluation  
This WP will evaluate how the project is addressing its overarching objectives and will 
consist of an external review by an approved agency with experience in evaluating EU level 
grants, in addition to regular internal reviews by the Project Steering Group.  
 
2.5 Data generation and outcome measures 
Several key outcome measures relating to the cascade of HCV care pre- and post-intervention 
will be examined in all WPs and settings, including: number and proportion of participants 
tested for HCV infection; number and proportion who are HCV positive; number and 
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proportion of HCV-positive patients who are: FibroScanned; referred to specialist care; 
attended specialist care; initiated HCV treatment; completed HCV treatment; achieved SVR; 
and number and proportion of deaths. Data will be generated through review of patients’ 
clinical records and through questionnaires and interviews with patients and healthcare 
providers.  
 
To facilitate clinical and research follow-up of participants, individuals contact details as well 
as the contact details of their GP and other support services will be collected at recruitment to 
the study. Follow-up data on access to and retention in HCV care (e.g. engagement with 
specialist services, treatment completion etc) will be collected by the research team from the 
participants’ health records and/or from follow-up questionnaires with participants. In the 
latter case, members of the research team will contact participants directly or via their support 
service/care team. 
 
Data on participants alcohol and drug use will be collected as part of the HepCheck and 
HepLink WPs and will form part of the patient referral information that is forwarded to 
hepatology/infectious diseases services. Detailed data on previous and current drug use 
(including drugs used, mode of administration, and frequency of use) will be collected as part 
of HepCheck and will enable an analysis of the potential associations between psychoactive 
substances use and HCV treatment outcomes. 
 
2.5.1  Health Economics 
Cost-effectiveness results will be expressed in terms of incremental cost of effectiveness 
ratios (ICERS) for each of the interventions, country-specific. The costs for each intervention 
will be estimated for each country/setting, including staff time spent on the intervention and 
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any relevant training and equipment costs. Treatment and care costs will be estimated 
following discussions with health care providers in each setting, and applying or adapting 
available costs from their or other EU settings. This will include costs for individuals that 
commence HCV treatment and those that do not. Health care benefits will be estimated in 
terms of quality adjusted life years saved (QALYS) with existing health utility data being 
used for different HCV disease stages. 
 
2.6 Ethical Considerations and Project Governance 
Ethical approval for the project has been received from our respective institutional review 
boards in the four fieldwork settings (i.e. Mater Misericordiae University Hospital, Dublin; 
Victor Babes Clinical Hospital for Infectious and Tropical Diseases, Bucharest; Hospital 
Universitario de Valme, Seville; North West - Haydock Research Ethics Committee, 
London).  
 
The project governance structure includes: (i) an International Advisory Board, composed of 
academics, clinicians, researchers, and representatives from relevant EU regulatory bodies 
and service-user organisations, to provide external oversight; (ii) a Project Steering Group, 
composed of WP leaders and site leaders, to provide internal oversight; and (iii) site-specific 
Project Management Teams to execute the project at each site.  
 
3. DISCUSSION 
We have described the focus of the Hepcare Europe project which is to develop, implement 
and evaluate interventions to enhance diagnosis, evaluation and treatment of HCV among 
PWID. PWID at risk of or infected with HCV often have complex needs. Many are unaware 
of their infection and those diagnosed often do not access specialist care. Recent 
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developments making HCV testing and evaluation more portable, less invasive and less 
reliant on specialists, enhance opportunities for further extension of HCV care to community 
settings to reach more patients. Hepcare Europe will design and evaluate outreach 
interventions to PWID and linked groups such as the homeless, through their points of 
contact with services in the community, e.g. prison, addiction services, primary care, hostels, 
and NGOs, in four European sites. Interventions will focus on enhancing HCV testing and 
evaluation of HCV disease in the community through education, point-of-care diagnostics, 
nurse outreach, and peer support, and will create shared care partnerships between 
secondary/tertiary and primary/community care to facilitate diagnosed patients to access 
treatment with the recently available DAAs. We will evaluate the feasibility, acceptability, 
potential efficacy, and cost-effectiveness of the interventions to improve HCV care processes 
and outcomes for PWID in a variety of settings in the four sites. 
 
While the Hepcare package of interventions aim to facilitate access to HCV treatment, the 
interventions will not change treatment eligibility criteria/recommendations. Decisions 
regarding HCV treatment of individual participants (i.e. treatment eligibility and treatment 
regimen) will be made by clinicians within the specialist hepatology/infectious diseases 
services to which HCV-infected participants are referred, and will be based on each 
region/country’s own national guidelines and policies. 
 
We have created a consortium of researchers and clinicians active in HCV care in Ireland, 
UK, Spain and Romania to support mutual learning and implementation of interventions 
across sites. The geography and history of the sites reflect the epidemiological and 
demographic diversity in risk populations and diversity in socio-economic and political 
environments across Europe. Sites vary in the structure of their health systems, models of 
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primary care, and policies around OST provision, harm reduction and access to the new DAA 
therapies. The UK, for example, has a well-developed social welfare programme and free 
health care through the National Health System. Ireland has a different model of care, with 
private and public health provision. Spain similarly has a private/public partnership in the 
provision of medical care and economic restrictions at present on its health care budget. 
Romania, as one of the newer members of the EU, still has some barriers in its systems of 
care. The logistics of developing integrated models of HCV care will differ across sites given 
their heterogeneity. Through our work and partnership, we will interrogate the issues, from 
testing to treatment, to implement new models of care that are adapted to the needs of PWID. 
 
To our knowledge, Hepcare Europe is the first multi-country European feasibility study 
examining interventions targeting all points in the HCV cascade of care from case-finding to 
treatment in diverse populations of PWID in a range of settings and countries. Other 
initiatives, such as The Extension for Community Healthcare Outcomes (ECHO) project (25, 
58), The Enhancing Treatment for Hepatitis C in Opioid Substitution Settings (ETHOS) 
study (23, 26), The Hepatitis C Assessment and Testing (HepCAT) project (59-61), and The 
Hepatitis C: Assessment through to Treatment (HepCATT) study (62, 63), and more recent 
studies in the Netherlands (64), Ukraine (65) and Scotland (66) are based in single countries 
or outside Europe, are focused on particular points in the HCV cascade of care (e.g. testing 
and referral or evaluation and treatment), and do not include the broad range of settings that 
Hepcare will. We hope that Hepcare with its breadth and scope will complement these more 
focused studies. 
 
3.1 Methodological considerations 
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As a pre-post feasibility study using mixed methods (mathematical modelling, qualitative 
data, cross-sectional, and longitudinal cohort elements), Hepcare does not employ a 
controlled trial design and lacks the scientific rigour of a RCT which could definitively 
determine effectiveness of the interventions. Also, as Hepcare interventions will be tailored 
according to the service infrastructure and population needs at each site, the implementation 
of interventions will not be homogenous. 
 
However, this is a real world service innovation project that aims to design and deliver 
interventions that will meet the needs of PWID populations in a variety of settings in four 
European sites. We have used the information gleaned from the literature and lessons learned 
from previous studies to generate a programme of work which we propose will deliver 
evidence-based interventions (i.e. POCT, FibroScan, nurse liaison) though means and 
modalities that will be convenient and adapted to the needs of PWID. 
 
Analyses of the Hepcare data will indicate which components of the Hepcare package of 
interventions work well and which don’t in different real world settings and populations. This 
will allow further refinement of the interventions. Cross-sectional analyses of the data will 
provide insights into the uptake of the interventions, while longitudinal data will provide 
information on the potential impact of the interventions over time, including the throughput 
of participants in the cascade of HCV care. Qualitative data will provide insights into the 
acceptability of the interventions to service-providers and service-users. Health economic 
analyses will indicate the cost-effectiveness of the interventions and how this may vary in 
different settings. 
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One possible threat to our study is the effect on efficacy outcome measures of the continuing 
evolution of national HCV treatment strategies and treatment eligibility criteria within each 
country, which will impact study outcome measures such as HCV treatment uptake and SVR, 
and may have knock-on effects on measures such as referral and attendance at specialist 
services. At the same time, this evolution provides opportunities for Hepcare Europe to 
influence the direction of national HCV strategies through its pro-active engagement with 
policy-makers. 
 
3.2 Implications for research, education, practice and policy 
As a service innovation project involving PWID populations in a variety of settings in four 
European sites, lessons learned from the project will provide real world contributions to 
implementation science regarding community-based interventions for HCV infection among 
PWID and linked groups. This may also inform the design of subsequent RCTs in this area. 
The findings from this feasibility study may inform integrated care research more broadly, 
particularly for marginalised groups.  
 
The interventions being developed as part of Hepcare have the potential to make an important 
impact on patient care through providing quality healthcare to marginalised populations who 
might otherwise go undiagnosed and untreated. 
 
The development of online educational materials will create a continuing resource for 
patients and healthcare professionals across Europe and may inform educational interventions 
for the aforementioned groups, in particular ensuring these are applicable for an international 
audience. 
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Lessons learned from the study can be incorporated into national and European guidelines 
and strategies for HCV. Consortium members are actively engaged with key stakeholders and 
policy-makers locally and nationally to ensure that Hepcare addresses key issues in their 
region/country and contributes to improved policy and practice. Preliminary learnings from 
the project have already informed national HCV screening guidelines in Ireland (35). 
 
3.3 Conclusions 
HCV infection is highly prevalent among PWID. Yet many PWID are unaware of their 
infection and few have received HCV treatment. The burden of HCV-related liver disease is 
growing and is expected to increase substantially in the next decade. The potential of the new 
HCV therapies to address this burden and to achieve the reductions in HCV-related mortality 
set out in the WHO GHSS will only be realised if the identification of HCV among PWID 
and linkage to care and treatment of those who are chronically infected is optimised.  
 
Taken together, our research findings will determine the feasibility, acceptability, likely 
efficacy, and cost-effectiveness of new models of care for engaging and retaining PWID in 
the cascade of HCV care. The analyses conducted as part of Hepcare Europe will be key in 
highlighting evidence for a scaled-up integrated care strategy for HCV infection in 
participating countries and in Europe. 
 
Key Issues 
 Hepatitis C (HCV) infection is associated with liver cirrhosis and hepatocellular 
carcinoma, and is highly prevalent among people who inject drugs (PWID). 
 Many PWID are unaware of their infection and few have received HCV treatment. 
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 The burden of HCV-related liver disease among PWID will substantially increase in 
the next decade. 
 Developments in HCV treatment have increased cure rates to >90%, in addition to 
shortening treatment times and improving safety profiles. 
 As many PWID remain unaware of their infection and/or are not accessing HCV care, 
it is evident that new strategies to reach such individuals are necessary, including new 
testing strategies to increase the number diagnosed, and improved care pathways to 
ensure those diagnosed are successfully linked to HCV evaluation and treatment. 
 Hepcare Europe is an EU-supported, service innovation project, involving 
collaboration between five institutions across four member states (Ireland, UK, Spain, 
Romania). The project aims to develop, implement and evaluate interventions to 
improve HCV identification, evaluation and treatment among PWID and linked 
groups such as the homeless and prisoners through their points of contact with 
services in the community in Dublin, London, Seville and Bucharest. 
 The geography and history of the four sites reflect the epidemiological and 
demographic diversity in risk populations and diversity in socio-economic and 
political environments across Europe. 
 Interventions will be tailored to the health service infrastructure and population needs 
at each site and will incorporate point-of-care-diagnostics, nurse outreach, 
community-based evaluation of HCV disease, health provider and patient education, 
peer support, and the development of integrated models of HCV care. 
 We will evaluate the feasibility, acceptability, potential efficacy and cost-
effectiveness of these interventions to get a better understanding of how 
improvements to the care of PWID can be achieved. 
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Table 1: HCV infection in the general population, PWID population and coverage of 
harm reduction measures in Hepcare Europe countries 
Countries CHC in 
general 
population 
HCV 
prevalence 
among PWID 
OST: 
Forms 
provided 
aOST: 
Coverage* 
aNSP: 
Coverage† 
 
Ireland 20,000-
30,000 
62-81% Methadone 
 
 
High: GTP (93-
GTP) 
Low: 46 (37-62) 
UK 214,000 52% Methadone, 
Buprenorphine, 
Diamorphine 
 
 
England 
High: 67 (62-72)  
Scotland  
Moderate: 23 
(21-27)  
Wales: NC 
Northern 
Ireland: NC 
England: NE 
Scotland 
High: 277 (249-
321)  
Wales: NC 
Northern Ireland: 
NC 
Romania 489,000 82.4% Methadone, 
Buprenorphine, 
Combination 
Buprenorphine/
Naloxone 
Low: 1 (<1-1)  Low: 18 (13-24)  
Spain 472,000 60-80% Methadone, 
Combination 
Buprenorphine/
Naloxone 
High: GTP Moderate:141 
(84-428)  
CHC: Chronic Hepatitis C; HCV: Hepatitis C Virus; OST: Opioid Substitution Treatment; 
NSP: Needle and syringe programmes; GTP – estimate greater than parity; NC: intervention 
exists and data on the extent of service provision were identified for this country, but no 
estimate of the prevalence of injecting drug use has been located for this country; 
NE: intervention exists in that country, but no data on the extent of service provision were 
located;  
*Number of OST clients per 100 PWID; †Number of needle-syringes distributed per PWID 
per year 
a (Larney, Peacock et al. 2017) (46) 
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Figure 1: Hepcare Europe Work Packages 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Primary Care  
Secondary care  
WP4: HepCheck 
(screening)  
WP5: HepLink       
(linkage to care)  
WP 7: HepFriend  
(peer advocacy  
support) 
WP 6: HepED  
(inter-professional 
education) 
WP8: HepCost 
WP 1 Coordination; WP 2 Dissemination; WP3 Evaluation 
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Table 2: Hepcare Europe Work Packages: Study populations, interventions, 
comparisons and key outcomes (PICO) 
Work 
Package 
Population Intervention Comparison Outcomes 
HepCheck  Prisoners 
(Dublin) 
 Homeless; 
PWID 
(Bucharest) 
 Underserved 
communities 
(London) 
 Homeless; 
PWUD 
(Spain) 
(Target: screening 
2000 individuals at-
risk of HCV across 
4 participating sites) 
 
Outreach and 
point of care 
testing of at-
risk populations 
 
Pre-post 
intervention 
N individuals screened 
for HCV 
N new cases of HCV 
detected 
N HCV-positive 
participants: 
 FibroScanned 
 Referred to 
hepatology/ID 
 Attended 
hepatology/ID 
 Started HCV 
treatment 
 Completed HCV 
treatment 
 Attained SVR 
HepLink  Patients on 
OST in GP 
practices / 
OST Centers  
Target : 24 
practices/centers  
and 240 patients 
across 4 
participating sites 
 
Outreach of a 
HCV-trained 
nurse into GP 
practices/OST 
centers to 
provide HCV 
education, 
community-
based 
evaluation of 
HCV disease, 
and assist with 
referral to 
specialist care 
Pre-post 
intervention 
 
N participants screened 
for HCV 
N participants HCV 
positive 
N HCV-positive 
participants: 
 FibroScanned 
 Referred to 
hepatology/ID 
 Attended 
hepatology/ID 
 Started HCV 
treatment 
 Completed HCV 
treatment 
 Attained SVR 
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PWID: People who inject drugs; PWUD: People who use drugs; HCV: Hepatitis C Virus; ID: 
Infectious Diseases; SVR: Sustained Virologic Response 
 
 
 
 
 
HepEd  Healthcare 
professionals 
(all sites) 
 Patients (all 
sites) 
 Peers (all 
sites) 
Development 
of educational 
resources for 
health care 
providers, 
patients and 
peers 
Pre-post 
masterclass 
survey 
Improvements in HCV 
knowledge 
HepFriend  Underserved 
communities 
(London) 
 Patients on 
OST/PWID 
(Seville) 
 Prisoners 
(Dublin) 
 Homeless 
(Bucharest) 
Peer support 
system to assist 
at-risk groups 
to engage with 
screening, 
assessment and 
treatment 
within 
HepCheck and 
HepLink 
Pre-post 
intervention 
N participants screened 
for HCV 
N HCV-positive 
participants: 
 FibroScanned 
 Referred to 
hepatology/ID 
 Attended 
hepatology/ID 
 Started HCV 
treatment 
 Completed HCV 
treatment 
 Attained SVR 
